Tandem Diabetes IPO Exceeds Opening Projections

As reported in +Mass Device, the underwriters of Tandem Diabetes Care's initial public offering exercised an over-allotment option of 1.2 million shares, adding $18 million to the IPO. For more on this story, read here. The Stradling IPO team was led by Shareholder Bruce Feuchter. Tandem is the first of two IPOs Stradling is leading this month.